Chargement en cours...
Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody...
Enregistré dans:
| Publié dans: | Exp Ther Med |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8082661/ https://ncbi.nlm.nih.gov/pubmed/33936262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2021.10037 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|